We are currently experiencing technical issues due to the Microsoft outage. This will affect delivery of multi-factor authentication emails, invoice emails and service emails. We apologise for the disruption.

Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesRocket Pharmaceuticals Inc

Rocket Pharmaceuticals Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
2.4106 USD -0.07 ( 2.80%)
Last update at 2026-11-12T15:36:00Z
VOLUME
156592
Market Cap
374.33M

Momentum Score

…

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States. It develops in vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), which is in phase 1; and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is a form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart, which is in preclinical stage. It also develops ex vivo lentiviral (LV) programs, which include programs for Leukocyte Adhesion Deficiency-I (LAD-I), a genetic disorder that causes the immune system to malfunction (RP-L201); Fanconi Anemia (FA), a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells (RP-L102); and Pyruvate Kinase Deficiency (PKD), a red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia (RP-L301). It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red de Enfermedades Raras, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and Temple University. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
2.38
Low
2.46
High
52 Week Price Range
2.53
Low
5.45
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
2.48
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.09
ROE
-4.77%
Net Debt
-52.68M
ROCE
-73.68%
Diluted EPS TTM
-0.17

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -223.12M -258.75M -245.59M -221.86M -169.07M
Net income -223.12M -258.75M -245.59M -219.38M -169.59M
Selling general administrative 86.50M 101.96M 73.32M 58.77M 41.77M
Selling and marketing expenses - - 1.72M - -
Gross profit -11.03M -9.38M -7.10M - -
Reconciled depreciation 11.03M 9.38M 6.94M 6.27M 5.37M
Ebit -221.23M -256.86M -243.72M -224.34M -167.25M
Ebitda -210.21M -247.49M -236.62M -213.69M -163.18M
Depreciation and amortization 11.03M 9.38M 7.10M 10.65M 4.07M
Non operating income net other - - - - 0.16M
Operating income -228.52M -273.20M -259.66M -224.34M -167.25M
Other operating expenses 228.52M 273.20M 259.66M 223.84M 166.25M
Interest expense 1.89M 1.89M 1.88M 1.91M 5.89M
Interest income 10.52M 16.34M 13.10M 3.89M 3.07M
Net interest income 8.62M 14.46M 12.30M 1.98M -2.82M
Income tax expense - -0.00M -245.59M -2.48M 0.52M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 217.49M 273.20M 259.66M 223.84M 166.25M
Cost of revenue 11.03M 9.38M 7.10M - -
Total other income expense net 5.39M 14.46M 14.06M 2.48M -1.82M
Net income from continuing ops -223.12M -258.75M -252.66M -221.86M -169.07M
Net income applicable to common shares - - - -221.86M -169.07M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 330.45M 527.70M 566.34M 551.81M 497.02M
Intangible assets 25.15M 25.15M 25.15M 25.72M -
Other current assets 3.81M 5.85M 5.05M 7.67M 3.32M
Total liab 53.23M 64.47M 73.77M 62.12M 42.30M
Total stockholder equity 277.22M 463.23M 492.57M 489.69M 454.72M
Other current liab 27.29M 36.20M 45.79M 36.66M 19.61M
Common stock 1.08M 1.06M 0.90M 0.79M 0.65M
Capital stock 1.08M 1.06M 0.90M 0.79M 0.65M
Retained earnings -1441.24M -1218.12M -959.37M -713.77M -491.91M
Other liab - - - 2.60M 0.08M
Good will 39.15M 39.15M 39.15M 39.15M 30.82M
Other assets - - - 1.95M 497.02M
Cash 77.56M 163.63M 55.90M 140.52M 232.69M
Total current liabilities 30.21M 40.68M 48.51M 39.17M 22.17M
Current deferred revenue - - -0.00M -36.66M -
Net debt -52.68M -138.14M -30.86M -117.65M -210.09M
Short term debt 2.92M 2.86M 2.72M 2.51M 2.55M
Short long term debt total 24.88M 25.50M 25.04M 22.87M 22.60M
Other stockholder equity 1717.41M 1680.22M 1450.72M 1203.03M 946.15M
Property plant equipment - - - 77.64M 72.35M
Total current assets 192.73M 378.18M 378.22M 364.06M 392.06M
Long term investments - 0.00M 34.32M 43.28M -
Net tangible assets - - - 424.81M 454.84M
Short term investments 111.37M 208.70M 317.27M 215.88M 156.05M
Accounts payable - 1.62M 0.00M 36.66M 0.48M
Accumulated other comprehensive income -0.03M 0.07M 0.32M -0.36M -0.16M
Common stock total equity - - - - 0.65M
Retained earnings total equity - - - - -491.91M
Non currrent assets other 0.48M 1.89M 1.37M 1.95M 1.80M
Non current assets total 137.72M 149.52M 188.12M 187.75M 104.96M
Capital lease obligations 24.88M 25.50M 25.04M 22.87M 22.60M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 104.21M 131.71M -65.85M -69.33M 26.57M
Change to liabilities - - - 9.67M -4.83M
Total cashflows from investing activities 103.77M 131.71M -98.07M -69.33M 18.85M
Total cash from financing activities 0.15M 185.74M 208.40M 155.29M 37.68M
Change to operating activities - - - -3.60M 1.44M
Net income -223.12M -258.75M -245.59M -221.86M -169.07M
Change in cash -86.10M 107.72M -84.58M -92.18M -64.63M
Begin period cash flow 165.00M 57.28M 141.86M 234.04M 298.67M
End period cash flow 78.90M 165.00M 57.28M 141.86M 234.04M
Total cash from operating activities -190.01M -209.72M -194.92M -178.14M -121.16M
Issuance of capital stock 0.00M 185.74M 315.86M 154.70M 26.35M
Depreciation 11.03M 9.38M 7.10M 6.27M 5.37M
Other cashflows from investing activities - 131.71M - -0.26M -0.10M
Sale purchase of stock -0.07M 0.00M 0.00M -0.05M 37.68M
Other cashflows from financing activities 0.21M -0.10M -0.13M 0.63M 11.33M
Change to netincome - - - 31.38M 45.17M
Capital expenditures 0.44M 5.86M 16.47M 8.62M 7.71M
Cash flows other operating - - - - 6.78M
Cash and cash equivalents changes - - - - -64.63M
Change in working capital -8.30M 1.92M 13.46M 6.08M -3.39M
Stock based compensation 37.06M 43.92M 39.41M 31.01M 29.24M
Other non cash items -6.68M -6.19M -9.28M 0.37M 13.53M
Free cash flow -190.45M -215.59M -211.39M -186.76M -128.88M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
RCKT
Rocket Pharmaceuticals Inc		 -0.07
2.80%		 2.41 - - - 1.02 39.79
NVO
Novo Nordisk A/S		 -0.54
1.32%		 40.55 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 -2.77
0.29%		 956.64 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

Rocket Pharmaceuticals Inc

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States. It develops in vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), which is in phase 1; and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is a form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart, which is in preclinical stage. It also develops ex vivo lentiviral (LV) programs, which include programs for Leukocyte Adhesion Deficiency-I (LAD-I), a genetic disorder that causes the immune system to malfunction (RP-L201); Fanconi Anemia (FA), a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells (RP-L102); and Pyruvate Kinase Deficiency (PKD), a red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia (RP-L301). It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red de Enfermedades Raras, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and Temple University. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

9 Cedarbrook Drive, Cranbury, NJ, United States, 08512

609 659 8001

https://www.rocketpharma.com

202

Name Title Year Born
Dr. Gaurav D. Shah M.D. CEO & Director 1975
Ms. Kinnari Patel M.B.A., MBA, Pharm.D., PharmD Pres & COO 1979
Mr. Martin Louis Wilson J.D. Gen. Counsel, Chief Compliance Officer & Sr. VP 1976
Mr. Jonathan Schwartz Chief Medical Officer & Sr. VP of Clinical Devel. 1964
Mr. John C. Militello CPA, CPA Interim Principal Financial Officer, VP, Sr. Controller, Treasurer & Principal Accounting Officer 1973
Mr. Mayo Pujols Chief Technical Officer, Exec. VP & Director NA
Mayur Kasetty M.B.A., M.D. Bus. Devel. & Operations and Investor Relations Lead NA
Ms. Jessie Yeung M.B.A. VP of Investor Relations & Corp. Fin. NA
Kevin Giordano Director of Corp. Communications NA
Ms. Isabel Carmona J.D. Sr. VP & Chief HR Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CJT
CAD 111.15
+12.71%
CLS
CAD 374.20
+8.33%
GRZ
CAD 4.90
+7.46%
CTC-A
CAD 218.05
+6.38%
FEC
CAD 7.42
+5.85%
TF
CAD 4.13
-19.65%
TLO
CAD 5.98
-15.06%
FSZ
CAD 2.45
-14.04%
XNDU
CAD 3.60
-8.86%
ITR
CAD 2.75
-8.50%

Equity Sectors*

  • Basic Materials

    -2.63%

  • Communication Services

    -0.79%

  • Consumer Cyclical

    +0.08%

  • Consumer Defensive

    -0.12%

  • Energy

    +0.52%

  • Financial Services

    -1.15%

  • Healthcare

    -1.74%

  • Industrials

    -0.64%

  • Real Estate

    -0.12%

  • Technology

    -0.51%

  • Utilities

    -0.02%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…